{"id":25811,"date":"2025-02-07T19:40:47","date_gmt":"2025-02-07T11:40:47","guid":{"rendered":"https:\/\/flcube.com\/?p=25811"},"modified":"2025-02-07T19:40:50","modified_gmt":"2025-02-07T11:40:50","slug":"bayer-files-for-ema-approval-of-kerendia-for-heart-failure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25811","title":{"rendered":"Bayer Files for EMA Approval of Kerendia for Heart Failure"},"content":{"rendered":"\n

Bayer AG (FRA: BAYN<\/a>) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).<\/p>\n\n\n\n

Global Registration and Clinical Trial Results<\/strong>
Finerenone, the first drug targeting the MR pathway, is already registered in more than 90 countries and regions worldwide, including China, Europe, Japan, and the US, for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The filing with the EMA leveraged positive results from the FINEARTS-HF study, a Phase III trial that demonstrated the effect of finerenone in preventing the risk of cardiovascular death and heart failure events in patients with LVEF \u2265 40%. Previously, these findings supported marketing filings for the drug with the same indication in the US and China simultaneously.<\/p>\n\n\n\n

Future Outlook<\/strong>
With this latest filing, Bayer continues to expand the potential use of Kerendia in addressing heart failure, a significant unmet medical need. The drug’s demonstrated efficacy in preventing cardiovascular events positions it well for further market adoption, reinforcing Bayer’s commitment to improving outcomes for patients with heart failure.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Bayer AG (FRA: BAYN) announced that it has made another market filing with the European…<\/p>\n","protected":false},"author":1,"featured_media":25812,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,69,888,38],"class_list":["post-25811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-cvd","tag-fra-bayn","tag-market-approval-filings"],"yoast_head":"\nBayer Files for EMA Approval of Kerendia for Heart Failure - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25811\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Files for EMA Approval of Kerendia for Heart Failure\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25811\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T11:40:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-07T11:40:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"663\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Files for EMA Approval of Kerendia for Heart Failure\",\"datePublished\":\"2025-02-07T11:40:47+00:00\",\"dateModified\":\"2025-02-07T11:40:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811\"},\"wordCount\":234,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0708-png.avif\",\"keywords\":[\"Bayer\",\"CVD\",\"FRA: BAYN\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25811#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25811\",\"name\":\"Bayer Files for EMA Approval of Kerendia for Heart Failure - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0708-png.avif\",\"datePublished\":\"2025-02-07T11:40:47+00:00\",\"dateModified\":\"2025-02-07T11:40:50+00:00\",\"description\":\"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25811\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0708-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0708-png.avif\",\"width\":1080,\"height\":663,\"caption\":\"Bayer Files for EMA Approval of Kerendia for Heart Failure\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25811#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Files for EMA Approval of Kerendia for Heart Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Files for EMA Approval of Kerendia for Heart Failure - Insight, China's Pharmaceutical Industry","description":"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25811","og_locale":"en_US","og_type":"article","og_title":"Bayer Files for EMA Approval of Kerendia for Heart Failure","og_description":"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).","og_url":"https:\/\/flcube.com\/?p=25811","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-07T11:40:47+00:00","article_modified_time":"2025-02-07T11:40:50+00:00","og_image":[{"width":1080,"height":663,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25811#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25811"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Files for EMA Approval of Kerendia for Heart Failure","datePublished":"2025-02-07T11:40:47+00:00","dateModified":"2025-02-07T11:40:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25811"},"wordCount":234,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=25811#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","keywords":["Bayer","CVD","FRA: BAYN","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25811#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25811","url":"https:\/\/flcube.com\/?p=25811","name":"Bayer Files for EMA Approval of Kerendia for Heart Failure - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=25811#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=25811#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","datePublished":"2025-02-07T11:40:47+00:00","dateModified":"2025-02-07T11:40:50+00:00","description":"Bayer AG (FRA: BAYN) announced that it has made another market filing with the European Medicines Agency (EMA) for its drug Kerendia (finerenone), a mineralocorticoid receptor (MR) antagonist. The German pharmaceutical giant is seeking approval in the EU for the drug to treat adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of \u226540%, including both mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25811#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25811"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=25811#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","width":1080,"height":663,"caption":"Bayer Files for EMA Approval of Kerendia for Heart Failure"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25811#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Files for EMA Approval of Kerendia for Heart Failure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0708-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25811"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25811\/revisions"}],"predecessor-version":[{"id":25813,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25811\/revisions\/25813"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/25812"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}